New AFib recommendations from the American College of Cardiology and American Heart Association covered significant ground—but there is still much more to learn, experts explained. 

Cardiologists, electrophysiologists, surgeons and patient representatives all worked together on the updated guidelines, which were published in both the Journal of the American College of Cardiology and Circulation.

The deal could also include additional clinical and regulatory milestone payments in the years ahead.

While TAVR and SAVR are reliable treatments for calcific aortic stenosis, some patients are not considered for those procedures due to severe comorbidities or a limited life expectancy. This is where the investigational Valvosoft device from Cardiawave enters the equation.

Medtronic acquired the technology behind the new device back in August.

Hospital readmissions, ER visits and major complications were all less likely when TAVR patients used a smartphone app to assist with their recovery. 

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.